BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

Search

Valley National Bancorp

Open

SectorFinance

12.05 -0.33

Overview

Share price change

24h

Current

Min

11.86

Max

12.25

Key metrics

By Trading Economics

Income

32M

195M

Sales

328K

892M

P/E

Sector Avg

11.802

54.048

EPS

0.31

Dividend yield

3.74

Profit margin

21.903

Employees

3,675

EBITDA

-4.6M

222M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+27.45% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.74%

4.84%

Next Earnings

23 Apr 2026

Next Dividend date

1 Apr 2026

Next Ex Dividend date

12 Jun 2026

Market Stats

By TradingEconomics

Market Cap

-142M

6.6B

Previous open

12.38

Previous close

12.05

News Sentiment

By Acuity

20%

80%

24 / 441 Finance

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Valley National Bancorp Chart

Past performance is not a reliable indicator of future results.

Related News

23 Mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 Mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 Mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 Mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 Mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 Mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 Mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 Mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

23 Mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 Mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 Mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 Mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 Mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 Mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 Mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 Mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 Mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 Mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 Mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 Mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 Mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 Mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 Mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 Mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 Mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 Mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 Mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Valley National Bancorp Forecast

Price Target

By TipRanks

27.45% upside

12 Months Forecast

Average 14.95 USD  27.45%

High 16 USD

Low 13 USD

Based on 11 Wall Street analysts offering 12 month price targets forValley National Bancorp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

9

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

8.73 / 8.9187Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

24 / 441 Finance

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Valley National Bancorp

Valley National Bancorp is a bank holding company for Valley National Bank. The Company's segment includes Consumer Lending, Commercial Lending, Investment Management, Corporate and Other Adjustments. The Consumer Lending segment comprises of residential mortgage loans and automobile loans, and to a lesser extent, home equity loans, secured personal lines of credit and other consumer loans (including credit card loans). The commercial lending segment is comprised of floating rate and adjustable rate commercial and industrial loans and construction loans, as well as fixed rate owner occupied and commercial real estate loans. The investment management segment comprised of fixed rate securities and, depending on its liquid cash position, federal funds sold and interest-bearing deposits with banks. The Corporate and other adjustments segment includes interest expense related to subordinated notes, amortization and impairment of tax credit investments as well as merger expenses.
help-icon Live chat